Sort
82,697 grants matching “vaccine development”
Tethering lentiviral restriction to Fc-mediated antibody responses
$707,673David T Evans · University Of Wisconsin-Madison · R01 · FY2022 · AI
MHC-bound, SIV-derived, CTL & HTL Epitopes
$707,662David I Watkins · University Of Wisconsin-Madison · R24 · FY2009 · RR
Vital Testing Core
$707,658Richard Grant · University Of Washington · U42 · FY2024 · OD
Multivalent Tick-Microbe targeted Lyme disease vaccines
$707,645Utpal Pal · Univ Of Maryland, College Park · R01 · FY2024 · AI
INTERNATIONAL TRAINING PROGRAM IN EPIDEMIOLOGY OF AIDS
$707,512Quarraisha Abdool Karim · Columbia University Health Sciences · D43 · FY2009 · TW
Characterizing Mucosal Changes in the FRT Leading to Increased HIV Acquisition
$707,472Thomas Hope · Northwestern University At Chicago · R01 · FY2019 · AI
Genetic predisposition to tuberculosis in Morocco
$707,441Jean-Laurent Casanova · Rockefeller University · U01 · FY2010 · AI
Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing Antibodies
$707,436Paul De Figueiredo · Texas A&M University · R01 · FY2021 · AI
SIV Transmission in Male NHP
$707,408Christopher Miller · University Of California At Davis · R01 · FY2014 · AI
Mycobacterial Genes, Antigens, and Vaccines
$707,314Harvard University (Sch Of Public Hlth) · R01 · FY2003 · AI
A mechanistic understanding of tuberculosis progression through bacterial reporter strains
$707,313David G Russell · Cornell University · R01 · FY2020 · AI
Center for Advancing COVID-19 health Equity Research
$707,280Jocelyn Denise Spates · Florida Agricultural And Mechanical Univ · U01 · FY2022 · FD
PET Probes Targeting Immune Cells for Imaging Tuberculosis
$707,272Carolyn J Anderson · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · AI
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma
$707,188William Gerald Teague · University Of Virginia · R01 · FY2023 · AI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies
$707,173Phillip Berman · University Of California Santa Cruz · R01 · FY2010 · DA
National Surveillance for Emerging Adenovirus Infections
$707,169Gregory Charles Gray · University Of Iowa · R01 · FY2006 · AI
Global sequence and surface antigenic diversity of Treponema pallidum outer membrane proteins
$707,165Juan C Salazar · University Of Connecticut Sch Of Med/Dnt · U19 · FY2023 · AI
Plant-derived vaccines against hepatitis C Cooperative *
$707,140Charles Joel Arntzen · Arizona State University-Tempe Campus · U19 · FY2007 · AI
RAPID VACCINATION OF HARD TO REACH POPULATI0NS
$707,046New York Academy Of Medicine · R01 · FY2004 · DA
Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C
$707,036T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Chlamydial Immunity and Vaccine Development
$707,019Harlan D Caldwell · Niaid Extramural Activities · Z01 · FY2007 · AI
Big data apprOaches fOr Safe Therapeutics in Healthy Pregnancies (BOOST-HP)
$706,955Judith Maro · Harvard Pilgrim Health Care, Inc. · R01 · FY2022 · HD
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains
$706,927Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2018 · AI
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
$706,927Wei Sun · Albany Medical College · R01 · FY2023 · AI
MBRS SCORE Program at UPR, Medical Sciences Campus
$706,916University Of Puerto Rico Med Sciences · S06 · FY2002 · GM